HLL Lifecare Ltd., a Union government ‘Mini Ratna’ public sector enterprise, has joined hands with UE LifeSciences, a women’s health innovator based in the U.S., to combat high mortality rates associated with breast cancer by introducing ‘iBreastExam,’ a device for early detection.
India witnesses more breast cancer-related deaths than any other country, with a significant number of women under the age of 50 succumbing to the disease, as per the Global Cancer Observatory study. The majority of cases are detected at a later stage, resulting in poor survival rates.
To find an innovative solution to this, HLL has empanelled UE LifeSciences for five years to bring iBreastExam to the forefront.
iBreastExam offers a standardised process for clinical breast examination, eliminating variabilities in the process. Given the challenges associated with mammogram screening in low-resource settings, the device serves as a practical alternative.
Clinically validated through independent studies involving over 25,000 women, iBreastExam incorporates ‘dynamic co-planar capacitive sensor technology’ to measure the differences in tissue elasticity in real-time at the point of care and without requiring manual interpretation. It helps in identifying and triaging for clinically relevant breast lumps in healthy, asymptomatic women.
Being hand-held, non-invasive and radiation-free, it helps to bring early detection to women in the communities where they live and work. iBreastExam also facilitates seamless patient follow-up by securely storing data on the cloud.
The device is designed for use by frontline health workers, nurses, primary care doctors and NGOs operating in the area of women’s health.
COMMents
SHARE